AI
Friday, October 15, 2010 12:52:59 PM
Might Roche have wanted to get out of the exclusivity for more immediate reasons? Specifically I was wondering if they would consider some sort of marketing deal with Vertex where they push Pegasys instead of PEG-Intron... I still remain in the camp that Danoprevir's still alive 
.
.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
